NASDAQ:CLXT - Calyxt Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.59 +0.17 (+1.27 %) (As of 02/20/2019 06:00 AM ET)Previous Close$13.42Today's Range$13.40 - $13.7052-Week Range$8.83 - $22.32Volume21,339 shsAverage Volume51,421 shsMarket Capitalization$442.63 millionP/E RatioN/ADividend YieldN/ABeta2.7 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, improved oil composition canola, herbicide tolerant canola, improved quality alfalfa and herbicide tolerant alfalfa, late blight resistant potatoes, cold storable/reduced browning potatoes, improved protein composition soybeans, drought tolerant soybeans, herbicide tolerant soybeans, and improved yield soybeans. The Company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was founded in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A. Receive CLXT News and Ratings via Email Sign-up to receive the latest news and ratings for CLXT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Agricultural chemicals Sub-IndustryN/A SectorConsumer Staples Current SymbolNASDAQ:CLXT Previous Symbol CUSIPN/A Webwww.calyxt.com Phone651-683-2807Debt Debt-to-Equity Ratio0.17 Current Ratio15.01 Quick Ratio15.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$510,000.00 Price / Sales867.89 Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book6.53Profitability EPS (Most Recent Fiscal Year)($1.12) Net Income$-25,980,000.00 Net Margins-6,256.67% Return on Equity-33.08% Return on Assets-26.44%Miscellaneous Employees35 Outstanding Shares32,570,000Market Cap$442.63 million OptionableNot Optionable Calyxt (NASDAQ:CLXT) Frequently Asked Questions What is Calyxt's stock symbol? Calyxt trades on the NASDAQ under the ticker symbol "CLXT." How were Calyxt's earnings last quarter? Calyxt Inc (NASDAQ:CLXT) announced its quarterly earnings data on Wednesday, August, 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The business earned $0.20 million during the quarter, compared to analyst estimates of $0.10 million. Calyxt had a negative net margin of 6,256.67% and a negative return on equity of 33.08%. View Calyxt's Earnings History. When is Calyxt's next earnings date? Calyxt is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Calyxt. What price target have analysts set for CLXT? 3 analysts have issued 12 month price objectives for Calyxt's stock. Their forecasts range from $13.00 to $27.00. On average, they expect Calyxt's share price to reach $19.3333 in the next year. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Price Targets for Calyxt. What is the consensus analysts' recommendation for Calyxt? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calyxt in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calyxt. Has Calyxt been receiving favorable news coverage? News headlines about CLXT stock have trended positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Calyxt earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. Who are some of Calyxt's key competitors? Some companies that are related to Calyxt include American Vanguard (AVD), CVR Partners (UAN), Marrone Bio Innovations (MBII), Evogene (EVGN), Arcadia Biosciences (RKDA), China Green Agriculture (CGA), SenesTech (SNES), Bion Environmental Technologies (BNET), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT), Eden Research (EDEN), Monsanto (MON), Syngenta (SYT), Terra Nitrogen (TNH) and Wynnstay Group (WYN). Who are Calyxt's key executives? Calyxt's management team includes the folowing people: Dr. Daniel Voytas Ph.D., Founder & Chief Science Officer (Age 56)Mr. James A. Blome, Chief Exec. OfficerMr. William Koschak, Chief Financial Officer (Age 49)Mr. Eric Dutang, Principal Accounting Officer (Age 45)Ms. Jennifer Moore, VP of Communications When did Calyxt IPO? (CLXT) raised $101 million in an IPO on Thursday, July 20th 2017. The company issued 6,100,000 shares at $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities served as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers. Who are Calyxt's major shareholders? Calyxt's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.19%), Mairs & Power INC (0.55%), Anchor Capital Advisors LLC (0.31%), Geode Capital Management LLC (0.28%), RMB Capital Management LLC (0.25%) and Millennium Management LLC (0.08%). Company insiders that own Calyxt stock include Alain Godard, Andre Choulika, Bryan WJ Corkal, Daniel F Voytas, Federico A Tripodi, Glenn R Bowers, Manoj Sahoo, Michel Arbadji, Philippe Dumont and SA Cellectis. View Institutional Ownership Trends for Calyxt. Which major investors are selling Calyxt stock? CLXT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Essex Investment Management Co. LLC and Essex Investment Management Co. LLC. Company insiders that have sold Calyxt company stock in the last year include Alain Godard, Andre Choulika, Bryan WJ Corkal, Daniel F Voytas, Federico A Tripodi, Glenn R Bowers, Manoj Sahoo, Michel Arbadji and Philippe Dumont. View Insider Buying and Selling for Calyxt. Which major investors are buying Calyxt stock? CLXT stock was acquired by a variety of institutional investors in the last quarter, including Anchor Capital Advisors LLC, RMB Capital Management LLC, Mairs & Power INC, Millennium Management LLC, Tibra Equities Europe Ltd, Paloma Partners Management Co, HRT Financial LLC and Bank of New York Mellon Corp. Company insiders that have bought Calyxt stock in the last two years include Philippe Dumont and SA Cellectis. View Insider Buying and Selling for Calyxt. How do I buy shares of Calyxt? Shares of CLXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Calyxt's stock price today? One share of CLXT stock can currently be purchased for approximately $13.59. How big of a company is Calyxt? Calyxt has a market capitalization of $442.65 million and generates $510,000.00 in revenue each year. The company earns $-25,980,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Calyxt employs 35 workers across the globe. What is Calyxt's official website? The official website for Calyxt is http://www.calyxt.com. How can I contact Calyxt? Calyxt's mailing address is 2800 MOUNT RIDGE ROAD, ROSEVILLE MN, 55113. The company can be reached via phone at 651-683-2807 or via email at [email protected] MarketBeat Community Rating for Calyxt (NASDAQ CLXT)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 160 (Vote Outperform)Underperform Votes: 168 (Vote Underperform)Total Votes: 328MarketBeat's community ratings are surveys of what our community members think about Calyxt and other stocks. Vote "Outperform" if you believe CLXT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLXT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: What is a Lock-Up Period?